Induction of IL-33 expression and activity in central nervous system glia
Open Access
- 13 June 2008
- journal article
- review article
- Published by Oxford University Press (OUP) in Journal of Leukocyte Biology
- Vol. 84 (3), 631-643
- https://doi.org/10.1189/jlb.1207830
Abstract
IL-33 is a novel member of the IL-1 cytokine family and a potent inducer of type 2 immunity, as mast cells and Th2 CD4+ T cells respond to IL-33 with the induction of type 2 cytokines such as IL-13. IL-33 mRNA levels are extremely high in the CNS, and CNS glia possess both subunits of the IL-33R, yet whether IL-33 is produced by and affects CNS glia has not been studied. Here, we demonstrate that pathogen-associated molecular patterns (PAMPs) significantly increase IL-33 mRNA and protein expression in CNS glia. Interestingly, IL-33 was localized to the nucleus of astrocytes. Further, CNS glial and astrocyte-enriched cultures treated with a PAMP followed by an ATP pulse had significantly higher levels of supernatant IL-1β and IL-33 than cultures receiving any single treatment (PAMP or ATP). Supernatants from PAMP + ATP-treated glia induced the secretion of IL-6, IL-13, and MCP-1 from the MC/9 mast cell line in a manner similar to exogenous recombinant IL-33. Further, IL-33 levels and activity were increased in the brains of mice infected with the neurotropic virus Theiler’s murine encephalomyelitis virus. IL-33 also had direct effects on CNS glia, as IL-33 induced various innate immune effectors in CNS glia, and this induction was greatly amplified by IL-33-stimulated mast cells. In conclusion, these results implicate IL-33-producing astrocytes as a potentially critical regulator of innate immune responses in the CNS.Keywords
Funding Information
- National Multiple Sclerosis Society (RG2569C5)
- National Institutes of Health (NS041593)
This publication has 64 references indexed in Scilit:
- IL-33 mediates antigen-induced cutaneous and articular hypernociception in miceProceedings of the National Academy of Sciences of the United States of America, 2008
- IL-33 reduces the development of atherosclerosisThe Journal of Experimental Medicine, 2008
- SHP-1 deficiency and increased inflammatory gene expression in PBMCs of multiple sclerosis patientsLaboratory Investigation, 2008
- IL-1 receptor accessory protein is essential for IL-33-induced activation of T lymphocytes and mast cellsProceedings of the National Academy of Sciences of the United States of America, 2007
- IL-33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling systemJCI Insight, 2007
- IL-33, the IL-1-like cytokine ligand for ST2 receptor, is a chromatin-associated nuclear factorin vivoProceedings of the National Academy of Sciences of the United States of America, 2007
- Inverse regulation of inducible nitric oxide synthase (iNOS) and arginase I by the protein tyrosine phosphatase SHP-1 in CNS gliaGlia, 2006
- Interleukin (IL)-4 and IL-13 up-regulate monocyte chemoattractant protein-1 expression in human bronchial epithelial cells: involvement of p38 mitogen-activated protein kinase, extracellular signal-regulated kinase 1/2 and Janus kinase-2 but not c-Jun NH2-terminal kinase 1/2 signalling pathwaysClinical and Experimental Immunology, 2006
- Role of Early Growth Response-1 (Egr-1) in Interleukin-13-induced Inflammation and RemodelingOnline Journal of Public Health Informatics, 2006
- The contribution of mast cells to the histamine content of the central nervous system: A regional analysisLife Sciences, 1982